English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: OA is now well recognized to involve an inflammatory component. Inflammatory cytokines produced by the synovium and chondrocytes appear to play pivotal roles in cartilage destruction. Some studies suggest that this local inflammation may be reflected systemically, and might be associated with the development or rate of progression of OA. We investigated whether baseline inflammatory markers predicted the rate of structural progression of OA in a cohort of healthy older adults unselected for joint disease. Methods: 396 men and women (60–70 years) from the Hertfordshire Cohort Study underwent knee radiographs in 1999–2003 and again a mean of 10.3 years later. Tibiofemoral joint Kellgren and Lawrence (KL anthropometric and lifestyle information was also available from baseline questionnaires. Results: The mean (S.D.) age of participants was 65.7 (2.6) years. hsCRP concentrations were normally distributed and fell in the normal range in over 99% of subjects; 75% subjects had an IL-6 concentration 1.5 pg/l at baseline. OA progression (an increase in KL there were no clear relationships between baseline IL-6 concentration and OA progression. Conclusion: Baseline inflammatory markers were not shown to be associated with rate of OA progression in older men and women. Larger prospective studies are required to confirm these findings. Disclosure statement: C.C. has provided consultancy services to Servier, Eli Lilly, Merck, Amgen, Alliance, Novartis, Medtronic, GSK, and Roche. All other authors have declared no conflicts of interest.

rheumatology

43. Baseline Inflammatory Markers do not Influence Rate of Progression of Knee Osteoarthritis Over 10 Years: Results from the Hertfordshire Cohort Study